Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Divestments (2022 - 2023)

VYNE Therapeutics' Divestments history spans 2 years, with the latest figure at $5.0 million for Q1 2023.

  • For Q1 2023, Divestments fell 68.26% year-over-year to $5.0 million; the TTM value through Dec 2023 reached $5.0 million, down 68.09%, while the annual FY2023 figure was $5.0 million, 68.09% down from the prior year.
  • Divestments reached $5.0 million in Q1 2023 per VYNE's latest filing, up from $1000.0 in the prior quarter.
  • In the past five years, Divestments ranged from a high of $15.8 million in Q1 2022 to a low of -$86000.0 in Q3 2022.